arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2007.11123stat.MEstat.AP
收藏

高维组学数据的结果导向疾病分型

Outcome-Guided Disease Subtyping for High-Dimensional Omics Data

Peng Liu, Yusi Fang, Zhao Ren, Lu Tang, George C. Tseng

摘要:

高通量微阵列和测序技术已被用于识别疾病亚型,这些亚型不能通过单独使用临床变量来观察。经典的无监督聚类策略主要关注在基因特征中具有相似模式的亚群的识别。然而,由于与不相关混杂因素(例如性别或年龄)对应的特征可能主导聚类过程,因此所得聚类可能会或可能不会捕获有临床意义的疾病亚型。这就产生了一个根本性的问题:我们能否找到一个由预先指定的疾病结果指导的亚型分型程序?现有的方法,如监督聚类,采用两阶段的方法,并依赖于任意数量的选定的功能与结果。在本文中,我们提出了一个统一的潜在生成模型来执行结果引导的疾病亚型从组学数据构建,这提高了有关感兴趣的疾病的亚型。特征选择嵌入在正则化回归中。数值计算和参数估计采用了一种改进的期望最大化算法。该方法同时进行特征选择、潜在亚型表征和结果预测。考虑到可能的离群值或违反混合高斯假设,我们将稳健估计使用自适应Huber或中位数截断损失函数。广泛的模拟和对具有转录组学和临床数据的复杂肺部疾病的应用证明了所提出的方法识别临床相关疾病亚型和适于探索精准医学的特征基因的能力。

英文摘要:

High-throughput microarray and sequencing technology have been used to identify disease subtypes that could not be observed otherwise by using clinical variables alone. The classical unsupervised clustering strategy concerns primarily the identification of subpopulations that have similar patterns in gene features. However, as the features corresponding to irrelevant confounders (e.g. gender or age) may dominate the clustering process, the resulting clusters may or may not capture clinically meaningful disease subtypes. This gives rise to a fundamental problem: can we find a subtyping procedure guided by a pre-specified disease outcome? Existing methods, such as supervised clustering, apply a two-stage approach and depend on an arbitrary number of selected features associated with outcome. In this paper, we propose a unified latent generative model to perform outcome-guided disease subtyping constructed from omics data, which improves the resulting subtypes concerning the disease of interest. Feature selection is embedded in a regularization regression. A modified EM algorithm is applied for numerical computation and parameter estimation. The proposed method performs feature selection, latent subtype characterization and outcome prediction simultaneously. To account for possible outliers or violation of mixture Gaussian assumption, we incorporate robust estimation using adaptive Huber or median-truncated loss function. Extensive simulations and an application to complex lung diseases with transcriptomic and clinical data demonstrate the ability of the proposed method to identify clinically relevant disease subtypes and signature genes suitable to explore toward precision medicine.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑